

Company registration number: CE019577

Charity registration number: 1186327

The Schinzel-Giedion Syndrome Foundation

(A company limited by guarantee)

Annual Report and Financial Statements

for the Year Ended 31 March 2025

MG Group (Professional Services) Limited
Chartered Accountants
166 College Road
Harrow
Middlesex
HA1 1BH

The Schinzel-Giedion Syndrome Foundation

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 5
Statement of Trustees' Responsibilities	6
Independent Examiner's Report	7
Statement of Financial Activities	8
Balance Sheet	9
Notes to the Financial Statements	10 to 17

The Schinzel-Giedion Syndrome Foundation

Reference and Administrative Details

Chairperson	Dr Nuala Summerfield
Trustees	Carina Rudolfsson Emma Hudson Dana Bradley Ms Aleksandra Blagunovski
Charity Registration Number	1186327
Company Registration Number	CE019577
Registered Office	The charity is incorporated in England. Lowfield Hall, Poles Lane Lowfield Heath Crawley RH11 0PX
Independent Examiner	Gavin Fernandes FCA, CTA MG Group (Professional Services) Limited Chartered Accountants 166 College Road Harrow Middlesex HA1 1BH

The Schinzel-Giedion Syndrome Foundation

Trustees' Report

Registered Charity Number: 1186327

Registered Charity Address:

Lowfield Hall, Poles Lane, Lowfield Heath, West Sussex, RH11 0PX, UK

Trustee Names:

- Nuala Summerfield, Founder & Chair and interim Treasurer
- Emma Hudson, Secretary (resigned 16 February 2025)
- Carina Rudolfsson, Social Media (resigned 04 February 2025)
- Aleksandra Blagunovski, Fundraising
- Dana Bradley, Community Engagement & Clinical Research

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements of the charitable company for the year ended 31 March 2025.

Objectives and activities

Public benefit

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

The Schinzel-Giedion Syndrome Foundation was established to represent children with Schinzel-Giedion Syndrome (SGS) and their families worldwide. The Foundation's mission is to provide support to families caring for a child with SGS, raise awareness of SGS, and facilitate and support scientific research. Our vision is for a future in which all children born with SGS will receive a rapid genetic diagnosis and have access to effective targeted therapies to ensure that they live longer, healthier and happier lives.

The Foundation is run entirely by volunteer trustees, the majority of whom are parents of children with SGS. <https://sgsfoundation.org/board-of-trustees/>

The Trustee Board is supported by an expert Scientific and Medical Advisory Board (SMAB) composed of seven individuals who are medical doctors and / or scientific researchers with relevant expertise and experience, and who offer their time to the Foundation in a voluntary capacity. <https://sgsfoundation.org/scientific-and-medical-advisory-board/>

The Schinzel-Giedion Syndrome Foundation

Trustees' Report

Risk Statement

In preparing the annual accounts, the Trustees have considered the major risks to which the charity is exposed and have satisfied themselves that appropriate systems and procedures are in place to manage those risks. The Trustees recognise that they have an ongoing responsibility to identify and manage the risks faced by the charity and have sought to discharge this responsibility by:

(a) preparing a risk register which identifies the principal risks to the charity and sets out the actions taken to mitigate each risk; and

(b) regularly reviewing the risk register at closed board meetings of the charity.

The main financial risk faced by the charity is the potential for insufficient funds or cash-flow constraints, which could impact the charity's ability to meet its commitments as they fall due.

Reserves Policy

The Trustees have established a reserves policy to ensure the charity maintains sufficient unrestricted funds freely available to meet its obligations as they fall due and to safeguard the continuity of its activities. Free reserves, defined as unrestricted funds excluding tangible fixed assets and designated funds, are held to provide working capital, manage cash-flow fluctuations, and mitigate the impact of unforeseen events or delays in income, reflecting the variable nature of donation-based funding. Having regard to the charity's annual expenditure for the year ended 31 March 2025 and the risks identified in the Risk Register, the Trustees consider an appropriate level of free reserves to be sufficient to cover at least six months of core operating costs, equivalent to approximately £30,000 - £35,000. The level of free reserves is monitored regularly through review of financial information and is formally reviewed at least annually, with appropriate action taken where reserves fall outside the target range.

Activities and Achievements During the Year

Family and Community Engagement

The Foundation held three virtual SGS family meetings during the year, in April 2024, November 2024, and March 2025. All meetings included live translation services to encourage inclusive participation from families across the global SGS community.

During the year, the trustees engaged a specialist social media company to support the charity's online presence on a paid basis. This decision was taken due to limited internal capacity following the resignation of the trustee previously responsible for social media, and the role has not yet been replaced. The trustees consider the cost to be reasonable and proportionate, helping to maintain community engagement and raise general awareness of Schinzel-Giedion Syndrome.

The Schinzel-Giedion Syndrome Foundation

Trustees' Report

Scientific Engagement

A virtual scientific meeting was convened during the year, bringing together an international group of clinicians and researchers with an interest in SGS. The meeting provided updates on SGS Foundation initiatives and current SGS research projects and facilitated discussion to encourage future scientific collaboration.

Research Activities

Throughout the year, the Foundation supported and progressed multiple international research initiatives spanning natural history, clinical care, and disease mechanisms, including the SGS Biorepository, Epigenetic Signature project, SGS Communication project, development of the SGS Standards of Care Guidelines, the Urinary Tract Anomalies Survey project, and the Lung Development and Function project.

Publications

International Expert Opinion on Standard of Care for Patients With Schinzel-Giedion Syndrome: A Modified Delphi Study (1/22/25)

Fiscal Sponsorship

The Foundation operates a fiscal sponsorship agreement with Rare Village Foundation, a Texas-based 501(c)(3) organisation, enabling US donors to make tax-deductible contributions in support of SGS-related activities.

Plans for the Coming Year

In the coming year, the Foundation will continue to support ongoing research projects, with a particular focus on raising awareness of the recently published SGS Standards of Care Guidelines and developing plain-language versions of these guidelines for families.

The Foundation also plans to initiate additional research projects to address important gaps in understanding the lived experience of individuals with SGS. These include a study exploring the patient and family journey following a cancer diagnosis in individuals with SGS, with a focus on the impact of managing cancer alongside an existing rare genetic condition. The Foundation will also support an SGS epilepsy phenotyping study to better characterise the types and frequency of seizures experienced by individuals with SGS. In parallel, the Foundation will work with Mayo Clinic to support the development of a collaborative relationship aimed at enabling Mayo Clinic to become an SGS Center of Excellence, strengthening clinical expertise and coordinated care for affected families.

The Foundation will continue to prioritise family support, including translation and interpretation services to ensure equitable access to information for families worldwide.

Clinical trial readiness activities will continue, particularly in relation to an antisense oligonucleotide (ASO) therapy for SGS currently in development, led by McGill University, Montreal.

Expected publications include:

- Schinzel-Giedion syndrome: communication, feeding and motor skills in 16 individuals
- A Plain Language Review of International Expert Opinion on Standard of Care for Patients with Schinzel-Giedion Syndrome
- Single cell transcriptional consequences of leukaemogenic SETBP1 mutations.

The Schinzel-Giedion Syndrome Foundation

Trustees' Report

Financial instruments

The trustees have considered the financial risks faced by the charity, including cash flow, credit, and liquidity risks.

The charity operates internationally and therefore holds and spends funds in more than one currency. The trustees manage this risk by keeping financial arrangements straightforward and ensuring that funds are held with reputable financial institutions.

Credit risk is considered low, as the charity's income is largely received in cash and it does not rely on significant outstanding receivables.

The trustees monitor cash balances regularly to ensure that sufficient funds are available to meet ongoing commitments and to support future activities.

During the year ended 31 March 2025, the charity reported total income of £68,345 and total expenditure of £64,185, resulting in a surplus of £4,160 for the year. While overall income was lower than the level projected in the annual budget, expenditure was carefully controlled and aligned with available funds. The charity therefore continued to deliver its charitable activities while maintaining financial stability. Total reserves increased to £118,652 at the year end, providing a strong and sustainable financial position to support ongoing and future activities.

The annual report was approved by the trustees of the charity on ^{26/01/2026} and signed on its behalf by:

Nuala Summerfield

.....
Dr Nuala Summerfield
Chairperson

The Schinzel-Giedion Syndrome Foundation

Statement of Trustees' Responsibilities

The trustees (who are also the directors of The Schinzel-Giedion Syndrome Foundation for the purposes of company law) are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

Company law requires the trustees to prepare financial statements for each financial year. Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including its income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards, comprising FRS 102 have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records that can disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees of the charity on ^{26/01/2026} and signed on its behalf by:

Nuala Summerfield

.....
Dr Nuala Summerfield
Chairperson

The Schinzel-Giedion Syndrome Foundation

Independent Examiner's Report to the trustees of The Schinzel-Giedion Syndrome Foundation ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2025.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of The Schinzel-Giedion Syndrome Foundation as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Gavin Fernandes

.....
Gavin Fernandes FCA, CTA
MG Group (Professional Services) Limited
Chartered Accountants
166 College Road
Harrow
Middlesex
HA1 1BH

27/01/2026
Date:.....

The Schinzel-Giedion Syndrome Foundation

Statement of Financial Activities for the Year Ended 31 March 2025 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted £	Restricted £	Total 2025 £
Income and Endowments from:				
Donations and legacies	3	27,362	40,983	68,345
Total income		27,362	40,983	68,345
Expenditure on:				
Charitable activities	4	(29,988)	(34,197)	(64,185)
Total expenditure		(29,988)	(34,197)	(64,185)
Net (expenditure)/income		(2,626)	6,786	4,160
Transfers between funds		(27,538)	27,538	-
Net movement in funds		(30,164)	34,324	4,160
Reconciliation of funds				
Total funds brought forward		86,525	27,967	114,492
Total funds carried forward	10	56,361	62,291	118,652
		Unrestricted funds	Restricted funds	Total 2024
	Note	£	£	£
Income and Endowments from:				
Donations and legacies	3	84,306	1,197	85,503
Total income		84,306	1,197	85,503
Expenditure on:				
Charitable activities	4	(59,106)	(5,777)	(64,883)
Total expenditure		(59,106)	(5,777)	(64,883)
Net income/(expenditure)		25,200	(4,580)	20,620
Transfers between funds		2,788	(2,788)	-
Net movement in funds		27,988	(7,368)	20,620
Reconciliation of funds				
Total funds brought forward		58,537	35,335	93,872
Total funds carried forward	10	86,525	27,967	114,492

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2024 is shown in note 10.

The notes on pages 10 to 17 form an integral part of these financial statements.

The Schinzel-Giedion Syndrome Foundation

(Registration number: CE019577)
Balance Sheet as at 31 March 2025

	Note	31 March 2025 £	31 March 2024 £
Current assets			
Debtors	8	62,312	56,324
Cash at bank and in hand		<u>57,360</u>	<u>59,188</u>
		119,672	115,512
Creditors: Amounts falling due within one year	9	<u>(1,020)</u>	<u>(1,020)</u>
Net assets		<u>118,652</u>	<u>114,492</u>
Funds of the charity:			
Restricted income funds			
Restricted funds		62,291	27,967
Unrestricted income funds			
Unrestricted funds		<u>56,361</u>	<u>86,525</u>
Total funds	10	<u>118,652</u>	<u>114,492</u>

For the financial year ending 31 March 2025 the charity was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the charity to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The financial statements on pages 8 to 17 were approved by the trustees, and authorised for issue on 25/01/2026 and signed on their behalf by:

Nuala Summerfield

.....
Dr Nuala Summerfield
Chairperson

The notes on pages 10 to 17 form an integral part of these financial statements.

The Schinzel-Giedion Syndrome Foundation

Notes to the Financial Statements for the Year Ended 31 March 2025

1 Charity status

The charity is limited by guarantee, incorporated in England, and consequently does not have share capital. Each of the trustees is liable to contribute an amount not exceeding £Nil towards the assets of the charity in the event of liquidation.

The address of its registered office is:

Lowfield Hall, Poles Lane

Lowfield Heath

Crawley

RH11 0PX

These financial statements were authorised for issue by the trustees on ^{26/01/2026}

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)) (issued in October 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Basis of preparation

The Schinzel-Giedion Syndrome Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Income and endowments

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

The Schinzel-Giedion Syndrome Foundation

Notes to the Financial Statements for the Year Ended 31 March 2025

Donations and legacies

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the charity before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that these conditions will be fulfilled in the reporting period.

Gifts in kind

The charity receives donated goods and services, which are recognized at fair value when received and disclosed in the financial statements in line with the Charities SOFA. These gifts are included in both income and expenditure, matching their usage in the charity's activities.

Donated services and facilities

The charity benefits from donated services and facilities, which are recognized at fair value when received. These are included in both income and expenditure in line with the Charities SOFA, reflecting the contribution of these resources to the charity's activities.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use. Other support costs are allocated based on the spread of staff costs.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Grant provisions

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty about either the timing of the grant or the amount of grant payable.

Support costs

Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, for example, allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.

The Schinzel-Giedion Syndrome Foundation

Notes to the Financial Statements for the Year Ended 31 March 2025

Taxation

The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the charity will not be able to collect all amounts due according to the original terms of the receivables.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Statement of Financial Activities over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the charity has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

The Schinzel-Giedion Syndrome Foundation

Notes to the Financial Statements for the Year Ended 31 March 2025

Foreign exchange

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are reported at the rates of exchange prevailing at that date.

The results of overseas operations are translated at the average rates of exchange during the period and their balance sheets at the rates ruling at the balance sheet date. Exchange differences arising on translation of the opening net assets and results of overseas operations are reported in other comprehensive income and accumulated in equity (attributed to non-controlling interests as appropriate).

Other exchange differences are recognised in the Statement of Financial Activities in the period in which they arise except for:

- 1) exchange differences on transactions entered into to hedge certain foreign currency risks (see above);
- 2) exchange differences arising on gains or losses on non-monetary items which are recognised in other comprehensive income; and
- 3) in the case of the consolidated financial statements, exchange differences on monetary items receivable from or payable to a foreign operation for which settlement is neither planned nor likely to occur (therefore forming part of the net investment in the foreign operation), which are recognised in other comprehensive income and reported under equity.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees discretion in furtherance of the objectives of the charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Financial instruments

Classification

Financial assets and financial liabilities are recognised when the charity becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charity after deducting all of its liabilities.

The Schinzel-Giedion Syndrome Foundation

Notes to the Financial Statements for the Year Ended 31 March 2025

Recognition and measurement

All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets and liabilities are only offset in the statement of financial position when, and only when there exists a legally enforceable right to set off the recognised amounts and the charity intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Financial assets are derecognised when and only when a) the contractual rights to the cash flows from the financial asset expire or are settled, b) the charity transfers to another party substantially all of the risks and rewards of ownership of the financial asset, or c) the charity, despite having retained some, but not all, significant risks and rewards of ownership, has transferred control of the asset to another party.

Financial liabilities are derecognised only when the obligation specified in the contract is discharged, cancelled or expires.

Fair value measurement

The best evidence of fair value is a quoted price for an identical asset in an active market. When quoted prices are unavailable, the price of a recent transaction for an identical asset provides evidence of fair value as long as there has not been a significant change in economic circumstances or a significant lapse of time since the transaction took place. If the market is not active and recent transactions of an identical asset on their own are not a good estimate of fair value, the fair value is estimated by using a valuation technique.

3 Income from donations and legacies

	Unrestricted funds General £	Restricted funds £	Total funds £
Donations and legacies;			
Donations from individuals	27,362	40,983	68,345
Total for 2025	27,362	40,983	68,345
Total for 2024	84,306	1,197	85,503

The Schinzel-Giedion Syndrome Foundation

Notes to the Financial Statements for the Year Ended 31 March 2025

4 Expenditure on charitable activities

		Unrestricted		Total 2025	Total 2024
		General	Restricted		
	Note	£	£	£	£
Charitable Activities		<u>29,988</u>	<u>34,197</u>	<u>64,185</u>	<u>64,883</u>

The Schinzel-Giedion Syndrome Foundation

Notes to the Financial Statements for the Year Ended 31 March 2025

5 Trustees remuneration and expenses

No trustees, nor any persons connected with them, have received any remuneration from the charity during the year.

6 Independent examiner's remuneration

	2025 £	2024 £
Independent Examiner's remuneration	1,020	1,020

7 Taxation

The charity is a registered charity and is therefore exempt from taxation.

8 Debtors

	31 March 2025 £	31 March 2024 £
Other debtors	<u>62,312</u>	<u>56,324</u>

9 Creditors: amounts falling due within one year

	31 March 2025 £	31 March 2024 £
Accruals	<u>1,020</u>	<u>1,020</u>

10 Funds

	Balance at 1 April 2024 £	Incoming resources £	Resources expended £	Transfers £	Balance at 31 March 2025 £
Unrestricted					
General	(86,525)	(27,362)	29,988	27,538	(56,361)
Restricted	<u>(27,967)</u>	<u>(40,983)</u>	<u>34,197</u>	<u>(27,538)</u>	<u>(62,291)</u>
Total funds	<u>(114,492)</u>	<u>(68,345)</u>	<u>64,185</u>	<u>-</u>	<u>(118,652)</u>

The Schinzel-Giedion Syndrome Foundation

Notes to the Financial Statements for the Year Ended 31 March 2025

	Balance at 1 April 2023 £	Incoming resources £	Resources expended £	Transfers £	Balance at 31 March 2024 £
Unrestricted funds					
General	58,537	84,306	(59,106)	2,788	86,525
Restricted funds	<u>35,335</u>	<u>1,197</u>	<u>(5,777)</u>	<u>(2,788)</u>	<u>27,967</u>
Total funds	<u>93,872</u>	<u>85,503</u>	<u>(64,883)</u>	<u>-</u>	<u>114,492</u>

11 Analysis of net assets between funds

	Unrestricted funds General £	Restricted funds £	Total funds at 31 March 2025 £
Current assets	57,381	62,291	119,672
Current liabilities	<u>(1,020)</u>	<u>-</u>	<u>(1,020)</u>
Total net assets	<u>56,361</u>	<u>62,291</u>	<u>118,652</u>
	Unrestricted funds General £	Restricted funds £	Total funds at 31 March 2024 £
Current assets	59,281	56,231	115,512
Current liabilities	<u>(1,020)</u>	<u>-</u>	<u>(1,020)</u>
Total net assets	<u>58,261</u>	<u>56,231</u>	<u>114,492</u>

12 Analysis of net funds

	At 1 April 2024 £	Cash Flow £	At 31 March 2025 £
Cash at bank and in hand	<u>59,188</u>	<u>(1,828)</u>	<u>57,360</u>
Net debt	<u>59,188</u>	<u>(1,828)</u>	<u>57,360</u>

The Schinzel-Giedion Syndrome Foundation

Detailed Statement of Financial Activities for the Year Ended 31 March 2025

	2025		2025	
	Unrestricted			Total
	General £	Restricted £	Total £	2024 £
Income and Endowments from:				
Donations and legacies (analysed below)	27,362	40,983	68,345	85,503
Total income	27,362	40,983	68,345	85,503
Expenditure on:				
Charitable activities (analysed below)	(29,988)	(34,197)	(64,185)	(64,883)
Total expenditure	(29,988)	(34,197)	(64,185)	(64,883)
Net (expenditure)/income	(2,626)	6,786	4,160	20,620
Transfers between funds (analysed below)	(27,538)	27,538	-	-
Net movement in funds	(30,164)	34,324	4,160	20,620
Reconciliation of funds				
Total funds brought forward	86,525	27,967	114,492	93,872
Total funds carried forward	56,361	62,291	118,652	114,492

This page does not form part of the statutory financial statements.

The Schinzel-Giedion Syndrome Foundation

Detailed Statement of Financial Activities for the Year Ended 31 March 2025

	2025			Total 2024 £
	Unrestricted funds General £	Restricted funds £	Total £	
<i>Donations and legacies</i>				
Appeals and donations	-	40,983	40,983	1,197
Appeals and donations	27,362	-	27,362	84,306
	<u>27,362</u>	<u>40,983</u>	<u>68,345</u>	<u>85,503</u>
	2025			Total 2024 £
	Unrestricted funds General £	Restricted funds £	Total £	
<i>Charitable activities</i>				
Direct costs	-	(3,613)	(3,613)	-
Direct costs	-	-	-	(6,738)
Computer and website costs	(581)	-	(581)	(883)
Trade subscriptions	(331)	-	(331)	(420)
Research funding	-	(30,715)	(30,715)	(3,855)
Research funding	(23,115)	-	(23,115)	(49,997)
Advertising	(4,899)	-	(4,899)	-
Accountancy fees	(1,020)	-	(1,020)	(1,020)
Bank charges	-	(9)	(9)	(111)
Foreign currency (gains)/losses	-	140	140	(1,811)
Foreign currency (gains)/losses	(42)	-	(42)	(48)
	<u>(29,988)</u>	<u>(34,197)</u>	<u>(64,185)</u>	<u>(64,883)</u>
	2025			Total 2024 £
	Unrestricted funds General £	Restricted funds £	Total £	
<i>Transfers between funds</i>				
Funds - Transfer from another fund	-	27,538	27,538	(2,788)
Funds - Transfer from another fund	(27,538)	-	(27,538)	2,788
	<u>(27,538)</u>	<u>27,538</u>	<u>-</u>	<u>-</u>

This page does not form part of the statutory financial statements.